|Headquarters||Binger Str. 173, 55216 Ingelheim Germany|
|Key people||Andreas Barner, Chairman of the board
Hubertus von Baumbach, board member
Wolfram Carius, board member
Allan Hillgrove, board member
Joachim Hasenmaier, board member
|Products||Human Pharmaceuticals and Animal Health|
|Revenue||€14.7 billion EUR (2012)|
|Operating income||€1.85 billion EUR (2012)|
C.H. Boehringer Sohn AG & Ko. KG is the parent company of Boehringer Ingelheim, which was founded in 1885 by Albert Boehringer in Ingelheim am Rhein, Germany. The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Still headquartered in Ingelheim, it operates globally with 140 affiliates and more than 46,000 employees. The company's key assets of interest are: respiratory disease, cardiovascular disease, Parkinson's disease, HIV, thromboembolic disease, cerebrovascular disease, oncology, diabetes and hepatitis. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. Boehringer Ingelheim is a full member of the European Federation of Pharmaceutical Industries and Associations EFPIA. The corporate logo of Boehringer Ingelheim depicts a stylized rendition of the central section of the imperial palace of Charlemagne.
Boehringer Ingelheim works in human pharmaceuticals, animal health and biopharmaceuticals. The group consists of 140 affiliated companies with more than 46,000 employees in all continents. Research and development (R&D) facilities were in five sites and 20 production plants in 13 countries. The research and development (R&D) facilities are located in Biberach/Germany, Ridgefield (Connecticut)/US, Vienna/Austria, Kobe/Japan and Milan/Italy. Over 7,000 employees work for the Boehringer Ingelheim in research and development.
- 1885: Albert Boehringer buys a small tartar factory in Ingelheim am Rhein; work begins on August 1.
- 1886: The factory commences production of tartaric acid for use in the food industry (e.g. in baking powder and carbonated beverages).
- 1893: Albert Boehringer renames the company C. H. Boehringer Sohn (CHBS) after his father, Christoph Heinrich Boehringer.
- 1893: While experimenting with the production of citric acid, lactic acid is formed. Albert Boehringer develops this process, with the intention of producing lactic acid on a larger scale.
- 1895: Lactic acid is produced on an industrial scale, and is successful commercially.
- 1917: Professor Heinrich Wieland, chemist, future Nobel Prize winner and cousin of Albert Boehringer, sets up the company’s research department.
- 1928: Albert Boehringer purchases Dr. Karl Thomae, a company based in Winnenden near Stuttgart.
- 1946: Dr. Karl Thomae GmbH is re-opened in Biberach an der Riss with a staff of 70 people.
- 1954: The company hires Fritz Fischer after he is released from jail.
- 1955: The Animal Health division is established as the company acquires Pfizer’s veterinary programme.
- 1971: The foreign subsidiary, Boehringer Ingelheim Pharmaceuticals, Inc is founded in Ridgefield, Connecticut (USA). This site is soon expanded, and becomes the company’s North American research centre.
- 1985: The Institute for Molecular Pathology (IMP) is established in Vienna; it opens in 1988.
- 1986: The biotechnological centre in Biberach begins production of biopharmaceuticals from cell cultures.
- 1998: The merging of Boehringer Ingelheim KG and Dr. Karl Thomae GmbH founds Boehringer Ingelheim Pharma KG.
- 2010: The company celebrates its 125th anniversary.
Boehringer Ingelheim is involved in publicly funded collaborative research projects with other industrial and academic partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox. The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.
Boehringer Ingelheim is a globally operating company, with 140 subsidiaries around the globe. The company's largest site and corporate headquarters is in Ingelheim am Rhein near Mainz and Frankfurt, Germany. Their main business regions are Europe, North America and Asia. The Research Institute of Molecular Pathology in Vienna (Austria), founded in 1985, has had Boehringer Ingelheim as its main sponsor since 1993.
Closure of drug manufacturing plant
In 2011 Ben Venue Laboratories in Bedford, Ohio, a division of Boehringer Ingelheim, voluntarily shut down after a U.S. Food and Drug Administration inspectors' report that found the plant had rusty tools, mold, and a barrel of 'unknown liquid', later found to be urine. The company invested US$300 million to upgrade the drug manufacturing plant, and limited production resumed in October 2012.
In 2005, the German magazine 'Capital' placed the company second in a 2005 list of Germany's best employers, and in the United Kingdom the company was placed 19th in The Sunday Times' 100 Best Companies To Work For. In 2006 the Science magazine (US) listed Boehringer Ingelheim as second place for top employers in the biotechnology and pharmaceutical industries.
In Germany, Brazil, the Netherlands, and the United Kingdom, Boehringer Ingelheim received recognition as one of the best employers for the year 2009. In 2009 the British newspaper ‘Sunday Times’ placed the company in the list ‘Best Places to Work’. The ‘Workforce Diversity Magazine’ and the ‘Careers & the disabled Magazine’ placed Boehringer Ingelheim as “A Top 50 Employer, Reader’s Choice: 2009”.
Key product lines
- Aggrenox (dipyridamole, acetylsalicylic acid)
- Combivent (ipratropium bromide, salbutamol)
- Flomax (tamsulosin)
- Micardis (telmisartan/telmisartan, hydrochlorothiazide)
- Micardis + Micardis Plus (telmisartan/telmisartan, hydrochlorothiazide)
- Mirapex (Sifrol) (pramipexole)
- Mobic (meloxicam)
- Pradaxa (dabigatran etexilate)
- Spiriva (tiotropium bromide)
- Trajenta (linagliptin)
- Twynsta (telmisartan, amlodipine)
- Viramune (nevirapine)
Consumer Health Care:
- Antistax(red vine leaf extract)
- Bisolvon (bromhexine)
- Buscopan , Buscapina (hyoscine butylbromide)
- Dulcolax (bisacodyl, sodium, picosulphate)
- Mucoangin (ambroxol)
- Mucosolvan (ambroxol)
- Pharmaton (standardised ginseng extract, vitamins, minerals, trace elements)
- Silomat DMP (dextrometorphan)
- Thomapyrin (acetylsalicylic acid, paracetamol, caffeine)
- CircoFLEX (recombinant vaccine (porcine circovirus type 2, PCV 2))
- Metacam (Meloxicam)
- Vetmedin (Pimobendan)
- "Boehringer Ingelheim Logo: Design and History". FamousLogos.us. Retrieved 2011-08-18.
- Mattes, William B. (2008). "Public Consortium Efforts in Toxicogenomics". In Mendrick, Donna L.; Mattes, William B. Essential Concepts in Toxicogenomics. Methods in Molecular Biology 460. pp. 221–238. doi:10.1007/978-1-60327-048-9_11. ISBN 978-1-58829-638-2. PMID 18449490.
- "InnoMed PredTox Member Organizations". Retrieved 2008-08-25.
- Innovative Medicines Initiative. "IMI Call Topics 2008". IMI-GB-018v2-24042008-CallTopics.pdf. European Commission. Retrieved 2008-08-25.
- "Ben Venue Laboratories – Voluntary Shutdown". US Food and Drug Adminstration. Web Page Last Updated: 11/30/2011. Retrieved 18 October 2012.
- THOMAS, KATIE (18 October 2012). "Lapses at Big Drug Factories Add to Shortages and Danger". New York Times. p. 10/18/12 N.Y. Times A1. Retrieved 18 October 2012.
- Gwynne, Peter (October 20, 2006), "TOP EMPLOYER SURVEY: It All Starts with Science",Science. Retrieved August 26, 2007.
- Boehringer Ingelheim Corporate website
- Boehringer Ingelheim Vetmedica United States Animal Health website
- Boehringer Ingelheim German website
- Boehringer Ingelheim USA website
- News-Centre (for journalists)
- Social Media at Boehringer Ingelheim
- CHC Products
- Boehringer Ingelheim Italia
- Boehringer Ingelheim Argentina
- Boehringer Ingelheim (Canada) Ltd.
- Boehringer Ingelheim Brazil
- Boehringer Ingelheim Spain
- Boehringer Ingelheim Mexico
- Site Buscopan Brazil
- Boehringer Ingelheim UK
- Boehringer Ingelheim Japan